One mechanism behind intrinsic or acquired resistance is the overexpression of anti-apoptotic proteins such as MCL-1 or BCL-XL which occurs in AML with FLT3-ITD mutation [10] or loss of TP53 [14], thereby mitigating the cellular dependence on BCL-2 [15]. This evidence concerns the gene BCL2 and acute myeloid leukemia.